



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

**FILE COPY**

May 10, 2006

William A. Rakoczy  
Christine J. Siwik  
Rakoczy Molino Mazzochi Siwik  
6 West Hubbard Street, Suite 500  
Chicago, IL 60610

Dear Mr. Rakoczy and Ms. Siwik:

Your petition requesting the Food and Drug Administration to make a determination that Wyeth Pharmaceuticals, Inc. discontinued its original formulation of Zosyn (piperacillen and tazobactam) for reasons unrelated to safety and efficacy and to allow companies to file Abbreviated New Drug Applications seeking approval to market the original Zosyn formulation, was received by this office on 05/09/2006. It was assigned docket number 2006P-0195/CP 1 and it was filed on 05/10/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe  
Division of Dockets Management  
Office of Management Programs  
Office of Management

2006P-0195

ACK 1